Article

The use of hematological effects in the development of minimal risk levels.

Division of Toxicology, Agency for Toxic Substances and Disease Registry, Atlanta, Georgia 30333, USA.
Regulatory Toxicology and Pharmacology (impact factor: 2.43). 09/1998; 28(1):61-6. DOI:10.1006/rtph.1998.1238 pp.61-6
Source: PubMed

ABSTRACT The Agency for Toxic Substances and Disease Registry (ATSDR) derives minimal risk levels (MRLs) to assist in evaluating risk of adverse health effects in individuals exposed to hazardous substances. MRLs are derived from published values identifying no-observed-adverse-effect levels (NOAELs) or lowest-observed-adverse-effect levels (LOAELs) in animal or human studies. The most sensitive end points are used. To date, 4 inhalation MRLs and 13 oral MRLs have been derived from hematological end points for 12 substances. This paper provides a brief overview of the hematological system, examples of hematological end points, and the MRL for substances with hematological end points.

0 0
 · 
0 Bookmarks
 · 
14 Views
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.

Full-text (2 Sources)

View
0 Downloads
Available from

Keywords

12 substances
 
13 oral MRLs
 
4 inhalation MRLs
 
adverse health effects
 
Disease Registry
 
hazardous substances
 
hematological end points
 
hematological system
 
lowest-observed-adverse-effect levels
 
minimal risk levels
 
MRL
 
MRLs
 
no-observed-adverse-effect levels
 
sensitive end points
 
substances
 
Toxic Substances
 

H G Abadin